Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
GHK-Cu
Copper Peptide, Glycyl-L-histidyl-L-lysine:copper(II)
A naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Levels decline significantly with age. Widely used in both injectable and topical forms for anti-aging.
A synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in tissue repair and regeneration. Widely used in the biohacking community for injury recovery.
Activates wound healing genes, promotes collagen and elastin synthesis, stimulates blood vessel growth, and has anti-inflammatory and antioxidant properties. The copper ion is essential for many enzymatic processes in tissue remodeling.
Promotes cell migration, blood vessel formation, and reduces inflammation. Upregulates actin, a cell-building protein critical for healing and cell migration to injury sites.
- Skin rejuvenation and anti-aging
- Wound healing
- Hair growth stimulation
- Collagen production
- Reducing inflammation
- Muscle and tendon repair
- Wound healing
- Reducing inflammation
- Hair regrowth (emerging research)
- Cardiac tissue repair
- Generally well-tolerated topically
- Injectable form has less safety data
- Potential copper toxicity at high doses
- Skin irritation possible with topical use
- Limited human clinical data
- Potential tumor growth concerns (theoretical)
- Injection site reactions
- Headaches reported anecdotally
GHK-Cu has a notably complex status after the April 15, 2026 FDA announcement. Injectable GHK-Cu is being removed from Category 2 (significant safety risks), while non-injectable GHK-Cu is simultaneously being removed from Category 1 (active evaluation). Both forms are scheduled for a unified PCAC review before February 2027. Topical cosmetic use is unaffected. Injectable use is now in regulatory gray zone — compounding pharmacies should not assume authorization until PCAC acts.
PCAC: By February 2027
On April 15, 2026, the FDA announced TB-500 will be removed from the Category 2 'significant safety risks' list effective April 22, 2026. Scheduled for PCAC review on July 23, 2026 to determine eligibility for the 503A bulk drug substances list. Compounding pharmacies should exercise caution until PCAC takes action.
PCAC: July 23, 2026
- Thymosin β4 promotes dermal healing
2007 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.